Paris, September 7th, 2010 – BioAlliance Pharma SA (Euronext Paris - BIO), a company
dedicated to the supportive care and treatment of cancer patients, today announced the
grant of a European patent protecting its product acyclovir Lauriad®. This patent is now
validated in all European countries; this first patent validation is a major step and the
procedures up to the grant are ongoing in the other major global areas, America and Asia.
This patent specifically protects the muco-adhesive tablet containing acyclovir, its process for
manufacturing and its clinical application.
«Acyclovir Lauriad® enables a treatment of recurrent herpes labialis on the basis of one tablet
application as soon as the first signs of infection appear. We are now looking for the
adequate commercial partner for this innovation in the herpes labialis market. The agreement
of the European and US Health Authorities, obtained this summer, to plan a registration
dossier submission in 2011, together with the progress of our patents are obviously key
steps in this process», stated Dominique Costantini, CEO of BioAlliance Pharma.
Intellectual Property constitutes a key asset of the Company and is at the heart of its R&D
projects. BioAlliance’s patent portfolio now comprises 34 families of published patents,
including 358 patent applications and patents related to innovative technologies or products.
Granted patents account for nearly 70% of this portfolio and provide BioAlliance Pharma’s
products with long term protection.
About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and
radiotherapy-induced complications and opportunistic infections in immunocompromised patients –
BioAlliance conceives and develops innovative products, especially in the hospital setting and for
orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition
is to become a leading player in these fields by coupling innovation to patient needs. The company’s
teams have the key competencies required to identify, develop and register drugs in Europe and the
USA; the products’ commercialization rights are licensed to international commercial partners invested
in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches
help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio:
(Oropharyngeal candidiasis in immunocompromised patients): Registered in 26
European countries, in Korea and in the United States
Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced
nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (Labialis herpes): Positive phase III final results
Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results
AMEP® (Invasive melanoma): Phase I Clonidine Lauriad®(Mucositis): Phase II Doxorubicine Transdrug®
(Liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).
BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
Tel.: +33 6 64 18 99 59